Outcomes
ADVERSE EVENTS, ALDOSTERONISM, SECONDARY, REMISSION
At follow-up after 1 month and 12 months, blood pressure and medication were recorded and serum potassium, creatinine, PAC, and PRC were measured. Confirmatory tests were performed if the ARR was positive. During follow-up, antihypertensive medication was adjusted by the physicians (Y.S., Q.L.) to achieve a target blood pressure of 140/90 mm Hg or below. For all the patients with PA, except those with UPA who had achieved complete biochemical remission after surgery, at the maximally tolerable dose of MRA, we added conventional antihypertensive agents to reach the target blood pressure if needed.The primary end point was the proportion of surgically treated patients with complete biochemical remission in the overall cohort after 12 months of follow-up. The secondary outcomes included (1) proportion of surgically treated patients who achieved complete clinical remission in the overall cohort after 12 months of follow-up; (2) daily defined doses (DDDs) of antihypertensive agents (including MRA), blood pressure, and proportion of patients reaching the target blood pressure in each group irrespective of their treatment after 12 months of follow-up; (3) adverse events during the study; and (4) rate of bilaterally successful AVS.Biochemical and clinical remission were defined based on the Primary Aldosteronism Surgery Outcome criteria.